BioSpark
- Company typePrivate
- Founded2022
- HeadquartersVancouver, Canada
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
BioSpark firmographics
Firmographics- Name
- BioSpark
- Legal name
- BioSpark AI Technologies
- Website
- https://www.biospark.ai/
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
BioSpark industry classification
Industry- Product category
- Oncology Real-World Evidence Platform
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)
- akta.pro secondary industry
- Translational Medicine & Biomarkers (HLAIALAF)
Keywords
Where BioSpark is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Markets served
BioSpark business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- Oncology Patient Journey Data: BioSpark provides structured oncology patient journey data to pharmaceutical companies, regulatory agencies, and academic institutions. The data is used for identifying adverse drug reactions, understanding real-world patient experiences, enhancing drug safety profiles, and supporting regulatory decision-making.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
BioSpark product offering
Product offeringCore offering
BioSpark provides OpenCase™, an NLP- and AI-powered platform that aggregates, filters, and synthesizes real-world oncology evidence from 60,000+ peer-reviewed case reports across 125+ countries, delivering structured patient journey datasets covering therapeutic switching, biomarker-guided options, and adverse drug reactions. The company also offers bespoke NLP and AI solutions that extract structured data from complex medical text collections, tailored to fit within client platforms and intended for pharmaceutical, regulatory, academic, and patient advocacy clients.
Product overview
BioSpark is a healthcare data intelligence company offering OpenCase™ as its core platform for aggregating and searching structured oncology case reports, complemented by bespoke NLP services for extracting structured data from medical text. OpenCase™ enables simple and accurate searches through thousands of curated electronic oncology case reports with intuitive visualizations of patient journeys, while the bespoke NLP service provides custom solutions for extracting meaningful data from complex medical text collections.
Differentiator
Problem solved
Functional benefit
Brands
- OpenCase™: The world's first tool to systematically aggregate, filter, and synthesize real-world evidence from case reports regarding oncology therapeutic adverse events. Currently holds 100,000 oncology therapeutic adverse events and provides simple and accurate searches to browse through thousands of curated electronic oncology case reports, with intuitive visualizations of patient journeys.
Quantifiable outcome
- Data from 60,000+ case reports documenting oncology patient journeys
- +2 more outcomes
Companies that use BioSpark
Customer profileSegments4 records
Ideal customer profiles4 records
BioSpark technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
BioSpark partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Pharmaceutical CompaniescoreBioSpark AI collaborates with pharmaceutical companies to leverage its novel data sets for identifying adverse drug reactions, understanding real-world patient experiences, and enhancing drug safety profiles. The collaboration enables pharmaceutical companies to access structured patient journey data for various research and regulatory purposes.
- Regulatory AgenciescoreBioSpark AI works with regulatory agencies such as the FDA and EMA to provide valuable insights from aggregated case reports that aid in regulatory decision-making processes for drug evaluation and approval.
- Academic InstitutionscoreCollaboration with academic institutions is essential for advancing medical research and enhancing patient care. BioSpark partners with academia to explore potential applications of its data sets in various research domains, leading to discovery of new treatment approaches and support for evidence-based medicine.
- Patient Advocacy Not-for-Profit OrganizationscoreIn the spirit of Open Science, BioSpark AI donates its real-world dataset to patient advocacy groups with the goal of expanding access and awareness about patient perspectives and experiences. This collaboration helps address patient needs, improve healthcare outcomes, and empower patients with knowledge.
Scale indicators7 records
Recent moves6 records
Expansion highlights4 records
BioSpark competitors and assessment
Company assessmentDirect peers
- TriNetX: Global health research network providing real-world patient data to pharma and academic researchers for cohort identification and outcomes studies. Comparable in serving pharma R&D with real-world patient journey data.
- Cota Healthcare: Oncology real-world evidence company providing curated patient journey data to pharma and providers. Comparable in oncology-specific data licensing and patient journey analytics.
- ConcertAI: Oncology real-world evidence and AI company serving pharma, providers, and regulators with curated patient-level datasets. Directly comparable in oncology RWE buyer base and analytic use cases.
- Syapse: Oncology RWE platform partnering with health systems, pharma, and regulators to enable precision oncology decisions. Comparable target customer set and oncology RWE orientation.
- Flatiron Health: Oncology-focused real-world evidence company (acquired by Roche) that aggregates structured EHR data for pharma and regulators. Directly comparable to BioSpark's oncology RWE positioning, though built on EHR rather than case-report data.
- Tempus Labs: AI-driven precision medicine company with oncology data, molecular profiling, and structured patient journey analytics serving pharma and providers. Closest large-scale peer to BioSpark's oncology data + AI thesis.
Broad incumbents
- Palantir Technologies: Data analytics platform with healthcare/life sciences deployments (e.g., for pharma R&D and public health agencies). Comparable AI-on-healthcare-data positioning but at a vastly larger scale and broader scope.
- Medidata Solutions: Clinical trial technology and RWE platform (Dassault Systèmes) serving pharma sponsors with structured trial data. Adjacent incumbent in clinical data for pharma R&D.
- IQVIA: Global life sciences analytics and RWE incumbent serving pharma, regulators, and providers across all therapeutic areas. Overlaps with BioSpark's pharma/regulator customer base but operates at vastly broader scale.
Emerging players
- nference: AI/biomedical NLP company that synthesizes unstructured clinical and scientific text into structured evidence for pharma R&D. Closest technology analogue to BioSpark's NLP-on-medical-text core capability.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
BioSpark social profiles
Digital presenceBioSpark financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioSpark leadership team
Management profileNumber of profiles
BioSpark funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioSpark M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioSpark
What does BioSpark do?
BioSpark provides OpenCase™, an NLP- and AI-powered platform that aggregates, filters, and synthesizes real-world oncology evidence from 60,000+ peer-reviewed case reports across 125+ countries, delivering structured patient journey datasets covering therapeutic switching, biomarker-guided options, and adverse drug reactions. The company also offers bespoke NLP and AI solutions that extract structured data from complex medical text collections, tailored to fit within client platforms and intended for pharmaceutical, regulatory, academic, and patient advocacy clients.
Is BioSpark a public or private company?
BioSpark is a private company. It is classified as unknown and is currently operating.
When was BioSpark founded?
BioSpark was founded in 2022. It employs 1 to 10 people.
Where is BioSpark based?
BioSpark is headquartered in Vancouver, Canada, in the North America region.
How does BioSpark make money?
One revenue line is on record: oncology Patient Journey Data.
Who are BioSpark's main competitors?
Direct peers on record are TriNetX, Cota Healthcare, ConcertAI, Syapse, Flatiron Health and Tempus Labs. Broad incumbents are Palantir Technologies, Medidata Solutions and IQVIA. nference is listed as an emerging player.
Does BioSpark have an API?
No public API is recorded for BioSpark.
What industry is BioSpark in?
BioSpark's product category is Oncology Real-World Evidence Platform. Its primary akta.pro industry code is HLAGAJAF, Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 5417 and its SIC code is 8731.